⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Form 8-K
sec.gov
MBRX
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
globenewswire.com
MBRX
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
globenewswire.com
MBRX